Karl Beutner

Karl Beutner, MD, Ph.D., is DermBiont’s Chief Executive Officer leading drug development efforts.

Karl brings more than 30 years of experience in various leadership and executive roles, most recently as Chief Medical Officer at Anacor Pharmaceuticals (acquired for $5.2B in 2016 by Pfizer).

Karl has had a major leadership role in the development of 12+ FDA-approved drugs, has helped create the clinical development plan for well over twenty new molecular entities, and has participated in or managed hundreds of clinical trials through the FDA process. He brings a track record of unparalleled leadership and success in topical drug development.

Karl is a practicing dermatologist and a member of the clinical faculty of the Department of Dermatology at UCSF.